Vascular Solutions to Present at the 30th Annual Canaccord Genuity Growth Conference

Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 30^th Annual Canaccord Genuity Growth Conference in Boston on Tuesday, August 10^th at 4:00pm (EST).

Howard Root, Chief Executive Officer of Vascular Solutions, will deliver the Company’s presentation. To hear the live audio webcast and view the slides of the Vascular Solutions’ presentation, go to the investor relations page of the Company’s web site http://www.vascularsolutions.com and click on the "IR Conferences” icon a few minutes prior to start time to download any necessary software.

About Canaccord Genuity

Canaccord Genuity is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients a unique perspective on global investment opportunities. More information is available at www.canaccordgenuity.com.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company focused on developing and delivering customized clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of over 50 products in three categories: catheter products (used in diagnosing and treating vascular disease), hemostat products (used in the control of bleeding during vascular procedures), and vein products (used in the treatment of varicose veins). Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists and vascular surgeons performing percutaneous procedures through its direct U.S. sales force and international distributor network.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2009 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of sustained profitability, exposure to intellectual property claims, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to www.vascularsolutions.com.